<DOC>
	<DOCNO>NCT00982358</DOCNO>
	<brief_summary>This study design support use valsartan diabetic population . Two different group study , one one without coronary artery disease ( CAD ) document angiography . The study intend demonstrate valsartan 320 mg anti-inflammatory potential , reduce inflammatory serum marker well inflammatory gene expression , show valsartan able improve metabolic parameter patient population . Furthermore , subgroup patient document CAD study want show valsartan improves coronary perfusion . 3 Objectives Primary objective : 1 . To demonstrate anti-inflammatory efficacy valsartan 160/320 mg test hypothesis superiority compare placebo reduction inflammatory marker Tumor necrosis factor alpha ( TNFα ) plasma 16 week treatment hypertensive patient type 2 diabetes mellitus . 2 . To demonstrate anti-inflammatory efficacy valsartan 160/320 mg test hypothesis superiority compare placebo reduction inflammatory marker Interleukin 6 ( IL-6 ) plasma 16 week treatment hypertensive patient type 2 diabetes mellitus . Secondary objective : 1 . To explore effect 160/320 mg valsartan parameter insulin sensitivity . 2 . To explore effect 160/320 mg valsartan additional inflammatory marker plasma [ e.g . C-Reactive protein ( CRP ) , soluble intracellular adhesion molecule-1 ( sICAM-1 ) , soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) , serum amyloid A ( SAA ) , soluble CD40 ligand ( sCD40L ) , fibrinogen , Interleukin 1β ( IL-1β ) , matrix metalloproteases -2 , -3 -9 ( MMP-2 , -3 , -9 ) , sE-selectin ) ] . 3 . To explore effect 160/320 mg valsartan inflammatory gene expression monocytes fat tissue . 4 . To explore effect 160/320 mg valsartan metabolic gene expression fat tissue . 5 . To explore effect 160/320 mg valsartan coronary perfusion , group patient angiographically document CAD .</brief_summary>
	<brief_title>Anti-Inflammatory Actions Valsartan Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female patient 30 80 year old , inclusive Controlled type 2 Diabetes Mellitus stable treatment least 4 week prior visit 1 Treated untreated stage 1 ( accord JNC VII Guidelines ) grade 1 ( accord ESH/ESC 2003 Guidelines ) hypertensive patient For one stratum : angiographically proven CAD Signed informed consent prior study procedure Hypertension classify stage 2 ( grade 2 ) high Normotensive patient , i.e . patient history high blood pressure , receive antihypertensive medication Treatment 2 antihypertensive medication Current treatment ARBs Glycated hemoglobin ( HbA1c ) &gt; 8.5 % Visit 1 Current treatment glitazones Myocardial infarction le 3 month prior Visit 1 Total cholesterol &gt; 7.8 mmol/l Past diagnosis systemic inflammatory disease Known suspect contraindication , include history allergy angiotensin receptor blocker History hypertensive encephalopathy cerebrovascular accident le 1 year prior Visit 1 Known KeithWagener grade III IV hypertensive retinopathy History heart failure Second third degree heart block without pacemaker Concomitant unstable angina pectoris Concurrent potential life threaten arrhythmia symptomatic arrhythmia Clinically significant valvular heart disease Evidence hepatic disease determine one following : ALT AST value &gt; 2 x ULN Visit 1 , history hepatic encephalopathy , history esophageal varix , history portocaval shunt Evidence renal impairment determine one following : serum creatinine &gt; 1.25 x ULN visit 1 , history dialysis , history nephritic syndrome Sodium value &lt; 132 mmol/L Visit 1 Serum potassium value &lt; 3.5 mmol/L &gt; 5.5 mmol/L visit 1 Any surgical medical condition might alter absorption , distribution , metabolism , excretion drug Female patient either postmenopausal one year surgically sterile , use effective contraceptive method barrier method spermicidal intrauterine device . Oral contraceptive use dermal implant mean contraception disallow Pregnant lactate female Any surgical medical condition , discretion investigator , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period History malignancy include leukemia lymphoma within 5 year prior Visit 1 History severe , life threaten disease within past five year Any previous history systemic autoimmune disease History drug alcohol abuse within last two year Participation investigational drug trial within one month prior visit 1</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>